Even in the long-term storage during example, indicates no loss aggregation of lower level stability of an antibody fragment, undetectable or antibody, and or loss with very little biological activity, the present invention, IL-9 poly and to provide a liquid formulation of the antibody or antibody fragment that binds specifically to immune peptide. Does not contain the common excipients and / or other,, the invention may include amino acid surfactants, sugars, other than histidine and sugar alcohols IL (pKa value of at least 7 and preferably less than 5) particular substantially and to provide a liquid formulation of the antibody or antibody fragment that binds specifically to immune -9 polypeptide. Failure, as well as the present invention, the one or more or IL-9R or disease characterized by this to use the liquid formulations of the present invention, or associated with aberrant expression and / or activity of IL-9 polypeptide further or their (respiratory infections preferably) infection failure, autoimmune diseases, inflammatory diseases, or proliferative disease, or disease characterized by this or related to aberrant expression and / or activity of subunit prevention of one or more symptoms, treatment, or I to provide a method of improvement. [Selection] Figure Figure 1本発明は、例え長期貯蔵時であっても、抗体又は抗体断片の安定性、検出できない程低いレベルの凝集、及び生物学的活性の非常に少ない喪失か又は喪失なしを示す、IL-9ポリペプチドへ免疫特異的に結合する抗体又は抗体断片の液体製剤を提供する。特に本発明は、実質的に界面活性剤、糖質、糖アルコール及びヒスチジン以外のアミノ酸(好ましくはpKa値が5未満及び7以上)、及び/又は他の一般的賦形剤を含有しない、IL-9ポリペプチドへ免疫特異的に結合する抗体又は抗体断片の液体製剤を提供する。更に本発明は、本発明の液体製剤を利用する、IL-9ポリペプチドの異常な発現及び/又は活性に関連するか又はこれを特徴とする疾患又は障害、並びにIL-9R又はその1以上のサブユニットの異常な発現及び/又は活性に関連するか又はこれを特徴とする疾患又は障害、自己免疫疾患、炎症疾患、増殖性疾患、もしくは感染症(好ましくは呼吸器感染症)、又はそれらの1以上の症状の予防、治療、又は改善の方法を提供する。【選択図】図1
